These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A double-blind, placebo-controlled study of alpidem, a novel anxiolytic of imidazopyridine structure, in chronically anxious patients. Casacchia M, Farolfi A, Priore P, Magni G, Stratta P, Cesana B, Rossi A. Acta Psychiatr Scand; 1989 Aug; 80(2):137-41. PubMed ID: 2572145 [Abstract] [Full Text] [Related]
3. Alpidem, a novel anxiolytic drug. A double-blind, placebo-controlled study in anxious outpatients. Bassi S, Albizzati MG, Ferrarese C, Frattola L, Cesana B, Piolti R, Farolfi A. Clin Neuropharmacol; 1989 Feb; 12(1):67-74. PubMed ID: 2565767 [Abstract] [Full Text] [Related]
4. Double blind, controlled study of the efficacy and safety of alpidem in the treatment of anxiety in schizophrenic in-patients. Minervini MG, Priore P, Farolfi A, Cesana B, Morselli PL. Pharmacopsychiatry; 1990 Mar; 23(2):102-6. PubMed ID: 1971117 [Abstract] [Full Text] [Related]
5. Clinical studies with the new anxiolytic alpidem in anxious patients: an overview of the European experiences. Musch B, Morselli PL, Priore P. Pharmacol Biochem Behav; 1988 Apr; 29(4):803-6. PubMed ID: 2901120 [Abstract] [Full Text] [Related]
6. Studies with alpidem in normal volunteers and anxious patients. Morton S, Lader M. Pharmacopsychiatry; 1990 May; 23 Suppl 3():120-3. PubMed ID: 1974071 [Abstract] [Full Text] [Related]
7. On the therapeutic action of alpidem in anxiety disorders: an overview of the European data. Morselli PL. Pharmacopsychiatry; 1990 May; 23 Suppl 3():129-34. PubMed ID: 1974073 [Abstract] [Full Text] [Related]
8. Alpidem and lorazepam in the treatment of patients with anxiety disorders: comparison of physiological and psychological effects. Morton S, Lader M. Pharmacopsychiatry; 1992 Jul; 25(4):177-81. PubMed ID: 1356277 [Abstract] [Full Text] [Related]
9. [Double-blind versus placebo comparison of single dose alpidem (50 mg or 75 mg) in a model of situational anxiety]. Regnier F, Chastel A, L'Heritier C, Magni G, Henry M. Therapie; 1989 Jul; 44(4):279-83. PubMed ID: 2574502 [Abstract] [Full Text] [Related]
10. A comparative study of alpidem, a nonbenzodiazepine, and lorazepam in patients with nonpsychotic anxiety. Diamond BI, Nguyen H, O'Neal E, Ochs R, Kaffeman M, Borison RL. Psychopharmacol Bull; 1991 Jul; 27(1):67-71. PubMed ID: 1677774 [Abstract] [Full Text] [Related]
11. Comparison of the efficacy, safety and withdrawal of alpidem and alprazolam in anxious patients. Frattola L, Garreau M, Piolti R, Bassi S, Albizzati MG, Borghi C, Morselli PL. Br J Psychiatry; 1994 Jul; 165(1):94-100. PubMed ID: 7802852 [Abstract] [Full Text] [Related]
12. Anxiolytics' effects on the actual driving performance of patients and healthy volunteers in a standardized test. An integration of three studies. O'Hanlon JF, Vermeeren A, Uiterwijk MM, van Veggel LM, Swijgman HF. Neuropsychobiology; 1995 Jul; 31(2):81-8. PubMed ID: 7760989 [Abstract] [Full Text] [Related]
13. A comparison of alpidem and placebo in relieving benzodiazepine withdrawal symptoms. Lader M, Farr I, Morton S. Int Clin Psychopharmacol; 1993 Jul; 8(1):31-6. PubMed ID: 8097214 [Abstract] [Full Text] [Related]
14. Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study. Naukkarinen H, Raassina R, Penttinen J, Ahokas A, Jokinen R, Koponen H, Lepola U, Kanerva H, Lehtonen L, Pohjalainen T, Partanen A, Mäki-Ikola O, Rouru J, Deramciclane Dose-Finding Study Group. Eur Neuropsychopharmacol; 2005 Dec; 15(6):617-23. PubMed ID: 15949921 [Abstract] [Full Text] [Related]
15. Effects of single doses of alpidem, lorazepam, and placebo on memory and attention in healthy young and elderly volunteers. Satzger W, Engel RR, Ferguson E, Kapfhammer H, Eich FX, Hippius H. Pharmacopsychiatry; 1990 May; 23 Suppl 3():114-9. PubMed ID: 1974070 [Abstract] [Full Text] [Related]
16. An evaluation of the anxiolytic SC 48,274 in generalized anxiety disorder (GAD). Cutler NR, Sramek JJ, Macpherson AE, Doss MG, Benes CO, Howard SF. Prog Neuropsychopharmacol Biol Psychiatry; 1994 Jul; 18(4):685-94. PubMed ID: 7938559 [Abstract] [Full Text] [Related]
17. An 8-Week, Randomized, Phase 2, Double-Blind, Sequential Parallel-Group Comparison Study of Two Dose Levels of the GABAA Positive Allosteric Modulator PF-06372865 Compared With Placebo as an Adjunctive Treatment in Outpatients With Inadequate Response to Standard of Care for Generalized Anxiety Disorder. Simen A, Whitlock M, Qiu R, Miceli J, Zumpano L, Du Metz M, Dua P, Binneman B. J Clin Psychopharmacol; 2019 Jul; 39(1):20-27. PubMed ID: 30531477 [Abstract] [Full Text] [Related]
18. Alpidem in the treatment of panic disorder. Schneier FR, Carrasco JL, Hollander E, Campeas R, Fallon B, Saoud JB, Feerick J, Liebowitz MR. J Clin Psychopharmacol; 1993 Apr; 13(2):150-3. PubMed ID: 8096527 [Abstract] [Full Text] [Related]
19. A double-blind, placebo-controlled study comparing the efficacy and safety of ipsapirone versus lorazepam in patients with generalized anxiety disorder: a prospective multicenter trial. Cutler NR, Sramek JJ, Keppel Hesselink JM, Krol A, Roeschen J, Rickels K, Schweizer E. J Clin Psychopharmacol; 1993 Dec; 13(6):429-37. PubMed ID: 7907097 [Abstract] [Full Text] [Related]